Discovering 3 Stocks That May Be Priced Below Their Estimated Value

In This Article:

As global markets have recently experienced broad-based gains, with U.S. indexes approaching record highs and smaller-cap indexes outperforming large-caps, investors are keenly focused on identifying opportunities that may be undervalued amidst the positive sentiment driven by strong labor market reports and stabilizing economic indicators. In this context of cautious optimism, discerning investors often seek stocks that are priced below their estimated value, offering potential for growth as market conditions evolve.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

HangzhouS MedTech (SHSE:688581)

CN¥62.11

CN¥124.14

50%

NBT Bancorp (NasdaqGS:NBTB)

US$50.08

US$99.93

49.9%

Truecaller (OM:TRUE B)

SEK47.98

SEK95.84

49.9%

Nordic Waterproofing Holding (OM:NWG)

SEK172.40

SEK344.25

49.9%

Kitron (OB:KIT)

NOK31.18

NOK62.32

50%

Power Root Berhad (KLSE:PWROOT)

MYR1.46

MYR2.92

50%

Intermedical Care and Lab Hospital (SET:IMH)

THB4.94

THB9.86

49.9%

Neosperience (BIT:NSP)

€0.57

€1.14

50%

BATM Advanced Communications (LSE:BVC)

£0.188

£0.38

50%

Audinate Group (ASX:AD8)

A$8.79

A$17.54

49.9%

Click here to see the full list of 926 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

Hotel ShillaLtd

Overview: Hotel Shilla Co., Ltd is a hospitality company operating in South Korea and internationally, with a market capitalization of ₩1.51 trillion.

Operations: The company generates revenue primarily from its Travel Retail (TR) segment, amounting to ₩3.30 trillion, and its Hotel & Leisure Sector, Etc., contributing ₩707.79 billion.

Estimated Discount To Fair Value: 47.1%

Hotel Shilla Ltd. is trading at ₩40,050, significantly below its estimated fair value of ₩75,702.96, representing a 47.1% discount. Despite interest payments not being well covered by earnings and a forecasted low return on equity of 15.2%, the company is expected to become profitable in the next three years with earnings growing at 113.19% annually and revenue growth outpacing the Korean market at 10.9% per year.

KOSE:A008770 Discounted Cash Flow as at Nov 2024
KOSE:A008770 Discounted Cash Flow as at Nov 2024

Hanall Biopharma

Overview: Hanall Biopharma Co., Ltd. is a pharmaceutical company that manufactures and sells pharmaceutical products both in South Korea and internationally, with a market cap of ₩1.78 trillion.

Operations: Revenue Segments (in millions of ₩):

Estimated Discount To Fair Value: 31.2%